| Oct 4 |
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
| Oct 1 |
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
|
| Sep 23 |
BioAtla out-licenses BA3362 to Context Therapeutics
|
| Sep 23 |
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
|
| Sep 16 |
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European ...
|
| Sep 9 |
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
|
| Sep 4 |
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky
|
| Aug 28 |
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 15 |
'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio
|
| Aug 14 |
Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2
|
